Molecular Characterization of Drug Resistance in Hepatitis B Viruses Isolated from Patients with Chronical Infection in Turkey

Basit Öğe Kaydı
dc.contributor.authorAsan, Ali
dc.contributor.authorSayan, Murat
dc.contributor.authorAkhan, Sıla
dc.contributor.authorKoruk, Suda Tekin
dc.contributor.authorAygen, Bilgehan
dc.contributor.authorSırmatel, Fatma
dc.contributor.authorEraksoy, Haluk
dc.date.accessioned2020-03-26T19:54:42Z
dc.date.available2020-03-26T19:54:42Z
dc.date.issued2018
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBackground: Hepatitis B virus (HBV) has a high mutation rate due to its unusual replication strategy leading to the production of a large number of virions with single and double mutations. The mutations, in turn, are associated with the development of drug resistance to nucleos(t)ide analogs (NUCs) in patients before and during NUCs therapy. Objectives: The current study aimed at investigating the molecular characterization of HBV in Turkish patients with chronic hepatitis B (CHB) infection. Methods: Polymerase chain reaction (PCR) amplification and direct sequencing procedures were used to analyze mutations. The detected drug resistance mutations were divided into the nucleos(t) ide analogs primary, partial, and compensatory resistance groups. The amino acid substitutions of hepatitis B surface antigen (HBsAg) were categorized into antiviral drug - associated potential vaccine-escape mutations (ADAPVEMs) and typical HBsAg amino acid substitutions, which included hepatitis B hyperimmunoglobulin (HBIg) - selected escape mutation, vaccine escape mutation, hepatitis B misdiagnosis, and immune - selected amino acid substitutions. Results: The number of patients included in the study was 528 out of which 271 (51.3%) were treatment - naive and 351 (66.3%) were hepatitis B e antigen (HBeAg) - negative. Moreover, 325 (61.6%) were males with a mean age of 38 years (range: 18 - 69). Primary, partial, and compensatory resistance to NUCs was reported in 174 (32.9%) patients. Six different ADAPVEM motifs were determined in both treatment - naive and treatment - experienced patients, namely, sF161L/rtI169X, sE164D/rtV173L, sL172L/rtA181T, sL173F/rtA181V, sS195M/rtM204V, and sS196L/rtM204I. The prevalence of ADAPVEMs and typical HBsAg escape mutations was 5.3% (n = 28) and 34.8% (n = 184), respectively. Conclusions: The analysis of drug resistance should constitute a fundamental part of the follow - up period of patients with CHB undergone treatment with NUCs. The surveillance of development of drug resistance mutations, while receiving treatment for hepatitis B is of paramount importance to monitor and control the emerging resistance.en_US
dc.identifier.doi10.5812/hepatmon.12472en_US
dc.identifier.issn1735-143Xen_US
dc.identifier.issn1735-3408en_US
dc.identifier.issue1en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.urihttps://dx.doi.org/10.5812/hepatmon.12472
dc.identifier.urihttps://hdl.handle.net/20.500.12395/36780
dc.identifier.volume18en_US
dc.identifier.wosWOS:000429311800001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherKOWSAR PUBLen_US
dc.relation.ispartofHEPATITIS MONTHLYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectHepatitis B Virusen_US
dc.subjectSequence Analysisen_US
dc.subjectHBsAgen_US
dc.subjectAntiviral Drug Resistanceen_US
dc.subjectChronic Hepatitis Ben_US
dc.subjectHBV Polymeraseen_US
dc.titleMolecular Characterization of Drug Resistance in Hepatitis B Viruses Isolated from Patients with Chronical Infection in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu